AGENDA

Uniform Formulary Beneficiary Advisory Panel
6 January 2011 @ 0900 AM

Naval Heritage Center Theater
701 Pennsylvania Ave. NW., Washington DC 20004

➢ Administrative Meeting (BAP members only @ 8:00 AM)
➢ Sign-In
➢ Welcome and Opening Remarks
➢ Public Citizen Comments
➢ Therapeutic Class Reviews

Members of the DoD Pharmacoeconomic Center will present relative clinical and cost effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.

The Committee made recommendations of the following drug classes during the November 2010 meeting:

➢ Drug Class Reviews:
  o Non-insulin Diabetes Drugs
    ▪ Metformin (Biguanides)
    ▪ Sulfonylureas
    ▪ Dipeptidyl-peptidase 4 (DPP-4) inhibitors
    ▪ Glucagon-like peptide-1 receptor agonists (GLP1RAs)
    ▪ Thiazolidinediones (TZDs)
    ▪ Meglitinides
    ▪ Alpha-glucosidase inhibitors (AGIs)
    ▪ Amylin agonists

➢ Designated Newly Approved Drugs:
  o Inhaled Corticosteroid/Long-Acting Beta Agonists—Dulera (mometasone/formoterol inhaler)
  o Antilipidemic-1s —Livalo (pitavastatin tablets)
  o Newer Sedative Hypnotic—Silenor (doxepin tablets)
- Narcotic Analgesic—Exalgo (hydromorphone extended release tablets)
- Antilipidemi-2s—Fibricor (fenofibric acid)
- Contraceptive Agents—Natazia (estradiol valerate/dienogest)

- Utilization Management—Prior Authorization:
  - Expansion of fentanyl prior authorization
  - Recommendation for fingolimod (Gilenya) prior authorization

- Panel Discussions

  The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.